Pmv Pharmaceuticals Inc (PMVP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $95.93M
Last updated: Nov 17, 2026 at 11:06 AM ET
Pmv Pharmaceuticals Inc (PMVP) Stock Forecast
Analysts expect Pmv Pharmaceuticals (PMVP) to earn -$1.23 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.23
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.99
- EPS consensus, revenue $4.77M
- Next report
- Mar 4, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.23 | -$1.42 to -$1.03 | 2 | N/A | N/A | 4 |
| Dec 31, 2027 | -$0.99 | -$1.15 to -$0.83 | 2 | $4.77M | N/A | 4 |
Quarterly Estimates
The EPS consensus is -$0.26 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.26 | -$0.33 to -$0.19 | 6 |
| Mar 31, 2027 | -$0.26 | -$0.30 to -$0.22 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.52.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.23 | -$1.28 | -$1.28 | -$1.41 | -$1.52 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.99 | -$0.88 | -$0.97 | -$0.97 | -$1.09 | N/A |
| Quarter ending Mar 31, 2027 | -$0.26 | -$0.24 | -$0.27 | -$0.27 | -$0.33 | N/A |
Frequently Asked Questions About PMVP
What is the PMVP stock forecast?
Consensus analyst estimates put Pmv Pharmaceuticals's EPS at -$1.23 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.
How do analysts rate PMVP stock?
Of 5 analysts covering Pmv Pharmaceuticals, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PMVP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.23, with estimates from -$1.42 to -$1.03 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.99, with estimates from -$1.15 to -$0.83 from 2 analysts.
What revenue do analysts expect from Pmv Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.77M.
How many analysts cover PMVP?
5 analysts rate Pmv Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PMVP pages: Overview, Earnings, Forecast, Financials, Competitors